The effect of food on the oral bioavailability of drugs: A review of current developments and pharmaceutical technologies for pharmacokinetic control

Therapeutic Delivery

Volumn 3, Issue 1, 2012, Pages 81-90

  Yasuji, Takehiko ^a   Kondo, Hiromu ^a   Sako, Kazuhiro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APREPITANT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBAMAZEPINE; CYCLODEXTRIN; DANAZOL; DILTIAZEM; FLAVONOID; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; ITRACONAZOLE; LACTULOSE; LOPINAVIR PLUS RITONAVIR; LYCOPENE; METHYLPHENIDATE; NANOPARTICLE; PHENYTOIN; PIPERINE; PROPYLENE GLYCOL; SEOCALCITOL; TAMSULOSIN; ZIPRASIDONE;

ATTENTION DEFICIT DISORDER; COMPUTER MODEL; CONTROLLED RELEASE FORMULATION; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; FOOD; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HONEY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSMOTIC CONTROLLED RELEASE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW;

EID: 84055176267     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.142     Document Type: Review

References (62)

1. Yu LX. Straughn AB, Faustino PJ. The effect of food on the relative bioavailability of rapidly dissolving immediate-release solid oral products containing highly soluble drugs. Mol. Pharm. 1, 357-362 (2004).
2. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 62, 1481-1502 (2002). (Pubitemid 34804156)
3. Lentz KA. Current methods for predicting human food effect. AAPS J. 10, 282-288 (2008).
4. Gamsiz ED, Ashtikar M, Crison J, Waltosz W, Bolger MB. Carrier RL. Predicting the effect of fed-state intestinal contents on drug dissolution. Pharm. Res. 27, 2646-2656 (2010).
5. Welling PG. Effect of food on drug absorption. Annu. Rev. Nutr. 16, 383-415 (1996).
6. Singh BN. Effect of food on clinical Pharmacokinetics. Clin. Pharmacokinet. 37, 213-255 (1999).
7. Adithan C. Food & drug bioavailability. Indian J. Med. Res. 121, 631-633 (2005). (Pubitemid 40846816)
8. Deferme S, Augustijns P. The effect of food components on the absorption of P-gp substrates; a review. J. Pharm. Pharmacol. 55, 153-162 (2003). (Pubitemid 36277751)
9. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res, 12, 413-420 (1995).
10. Lobenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50, 3-12 (2000). (Pubitemid 30326685)
11. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Poor aqueous solubility - an industry wide problem in drug discovery. Am. Pharm. Rev. 5, 82-85 (2002).
12. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113-120 (2003). (Pubitemid 36184748)
13. Yasuji T, Haslam J, Kajiyama A, McIntoshi MP, Rajewski RA. Preliminary evaluation of polymer-based drug composite production by coacervate desolvation with supercritical carbon dioxide. J. Pharm. Sci. 95, 581-588 (2006).
14. Zia V, Rajewski RA, Stella VJ. Effect of cyclodextrin charge on complexation of neutral and charged substrates; comparison of (SBE)-7M-b-CD to HP-b-CD. Pharm. Res. 18, 667-673 (2001). (Pubitemid 32595797)
15. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of Paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of p-glycoprotein inhibitors. Pharm. Res. 21, 261-270 (2004). (Pubitemid 38221971)
16. Wu CW, Benet LZ. Predicting drug deposition via application of BCS: transport/absorption/ elimination interplay and development of a biophamaceutics drug disposition classification system. Pharm. Res. 22, 11-23 (2005). (Pubitemid 40558141)
17. Smide JH, Offringa JC, Crommelin DJ. Dissolution kinetics of griseofulvin in sodium dodecylsulphate solutions. J. Pharm. Sci. 76, 711-714 (1987). (Pubitemid 18026981)
18. Kassem MA, Mattha AG, El-Nimr AEM. Study of the influence of sodium taurocholate (STC) and sodium glycocholate (SGC) on the mass transfer of certain drugs. Digoxin. Int. J. Pharm. 12, 1-9 (1982). (Pubitemid 12058121)
19. Yano K, Masaoka Y, Kataoka M, Sakuma S, Yamashita S. Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes. J. Pharm. Sci. 99, 1336-1345 (2010).
20. Sugano K. Computational oral absorption simulation for low-solubility compounds. Chem. Biodivers. 6, 2014-2029 (2009).
21. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/ elimination/ transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60, 717-733 (2008).
22. Marasanapalle VP, Crison JR, Ma J. Investigation of some factors contributing to negative food effects. Biopharm Drug Dispos. 30, 71-80 (2009).
23. Marasanapalle VP, Crison JR, Devarakonda KR et al. Predictive models for drugs exhibiting negative food effects based on their biopharmaceutical characteristics. Drug Develop Ind Pharm. 37, 1-10 (2011).
24. Bruesewitz C, Funke A, Kuhland U et al. Comparison of permeation enhancing strategies for an oral factor Xa inhibitor using the Caco-2 cell monolayer model. Eur J. Pharm. Biopharm 64, 230-237 (2006).
25. Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to p-glycoprotein: the role of efflux transport in the oral absorption of BCS Class III drugs. Molecular Pharmaceutics 6, 10-28 (2008).
26. Kawai Y, Fujii Y, Tabata F et al. Profiling and trend analysis of food effects on oral drug absorption considering micelle interaction and solubilization by bile micelles. Drug Metab. Pharmacokinet. 26, 180-191 (2011).
27. Deferme S, Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55, 153-162 (2003). (Pubitemid 36277751)
28. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. J. Pharm. Sci. 100, 3843-3853 (2011).
29. Bailey DG, Spence JD, Edger B. Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12, 357-362 (1989). (Pubitemid 20014984)
30. Harley MJ, Cancalon P, Windmer WW. The effect of grapefruit juice on drug diposition. Expert Opin. Drug Metab. Taxicol. 7, 267-286 (2011).
31. Stewart CC, Strother A. Glucose consumption by rates decreases cytochrome P450 enzyme activity by altering hepatic lipid. Life Sci. 64, 2163-2172 (1999). (Pubitemid 29236576)
32. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK. Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits. Indian J. Exp. Boil. 40, 1164-1168 (2002). (Pubitemid 35169732)
33. Koumaravelou K, Adithan C, Shashindran CH, Asad M, Abraham BK. Effect of honey on carbamazepine kinetics in rabbits. Indian J. Exp. Boil. 40, 560-563 (2002). (Pubitemid 34468119)
34. Sukrit SKG. Influence of honey on the pharmacokinetics of phenitoin in healthy rabbits. Methods FInd Exp. Clin. Pharmacol.25, 367-370 (2003).
35. Jaganathan SK. Can flavonoids from honey alter multidrug resistance? Med. Hypotheses 76, 535-537 (2011).
36. Han HK. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs. Expert Opin. Drug Metab. Toxicol. 7, 721-729 (2011).
37. Won CS, Oberlies NH, Paine MF. Influence of dietary substances on intestinal drug metabolism and transport. Cancer Chemother. Pharmacol. 11, 778-792 (2010).
38. Dressman JB, Amidon GL, Reppas C. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res. 15, 11-22 (1998). (Pubitemid 28080861)
39. Nicolaides E, Symillides M, Dressman JB, Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 18, 380-388 (2001). (Pubitemid 32595828)
40. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human GI tract: an update. Pharm. Res. 25, 1663-1676 (2008).
41. Sreenivasulu K, Raghu P. Nair KM. Polyphenol-rich beverages enhance zinc uptake and metallothinein expression in Caco-2 cells. J. Food Sci. 75, H123-H128 (2010).
42. Aspenstrom-Fagerlund B, Sundstrom B, Tallkvist J et al. Fatty acids increase paracellular absorption of aluminium across Caco-2 cell monolayers. Chem. Biol. Interact. 181, 272-278 (2009).
43. Deat E, Blanquet-Diot S, Jarrige JF et al. Combining the dynamic TNO-gastrointestinal tract system with a Caco-2 cell culture model: application to the assessment of lycopene and a-tocopherol bioavailability from whole food. J. Agric Food Chem. 57, 11314-11320 (2009).
44. Waldman SA, Morganroth J. Effects of food on the bioequivalence of differet verapamil sustained-release formulations. J. Clin. Pharmacol. 35, 163-169 (1995).
45. Buice RG, Subramanian VG, Lane E. Bioequivalence of highly variable drug: an experience with nadolol. Pharm. Res. 13, 1109-1115 (1996). (Pubitemid 26259016)
46. Hosney EA, El-Sayed YM, Al-Meshal MA. Effect of food on bioavailability of bioadhesive-containing indometachin tablet in dogs. Int. J. Pharm. 112, 87-91 (1994). (Pubitemid 24292916)
47. Wu Y, Loper A, Landis E et al. The role of biopharmaceutics in the development of a clinical nanoparticles formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146 (2004). (Pubitemid 39361543)
48. Woo JS, Song YK, Hong JY, Lim SJ, Kim SK. Reduced food effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur. J. Pharm. Sci. 33, 159-165 (2008).
49. Charman WN, Rogge MC, Boddy AW, Berger BM. Effect of food and a monoglyceride emulsion formulation on danazol bioavailability. J. Clin. Pharmacol. 33, 381-386 (1993). (Pubitemid 23141537)
50. Grove M, Müllertz A, Pedersen GP, Nielsen JL. Bioavailability of seocalcitol III. administration of lipid-based formulations to minipigs in the fasted and fed state. Eur. J. Pharm. Sci. 31, 8-15 (2007). (Pubitemid 46601865)
51. Perlman ME, Murdande SB, Gumkowski MJ et al. Development of a selfemulsifying formulation that reduces the food effect for torceptrapid. Int. J. Pharm. 351, 15-22 (2008). (Pubitemid 351186838)
52. Thombre G, Herbig SM, Alderman JA. Improved ziprasidone formulations with enhanced bioavailability in fasted state and reduce food effect Pharm. Res. doi:10.1007/ s11095-011-0505-0507 (2011).
53. Klein CE, Chiu YL, Awni W et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immyne. Defic. Sybdr. 44, 401-410 (2007). (Pubitemid 46555374)
54. Auiler JF, Lu K, Lynch JM, Gelotte CK. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study. Curr. Med. Res. Opin. 18, 311-316 (2002).
55. Malaterre V, Ogorka J, Loggia N, Gurny R. Oral osmotically driven systems: 30 years of development and clinical use. Eur. J. Pharm. Biopharm. 73, 311-323 (2009).
56. Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin. an update of its role in the management of lower urinary tract symptoms. Drugs 62, 135-167 (2002). (Pubitemid 34169429)
57. Michel MC, Korstanje C, Krauwinkel W et al. The pharmacokinetic profile of Tamsulosin Oral Controlled Absorption System (OCAS®).Euro. Urol. Suppl. 4, 15-24 (2005). (Pubitemid 40125734)
58. Sako K, Nakashima H, Sawada T, Fukui M. Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. Pharm. Res. 13, 594-598 (1996).
59. Tanno FK, Sakuma S, Masaoka Y et al. Site-specific drug delivery to the middle-to-lower region of the small intestine reduces food-drug interactions that are responsible for low drug absorption in the fed state. J. Pharm. Sci. 97, 5341-5353 (2008).
60. Mano Y, Usui T, Kamimura H. Hepatobiliary taransport of YM466, a novel factor Xa inhibitor, in rats. Eur. J. Drug Metab. Pharmacokinet. 31, 117-121 (2006).
61. Katsuma M, Watanabe S, Kawai H, Takemura S, Masuda Y, Fukui M. Studies on lactulose formulation for colon-specific drug delivery. Int. J. Pharm. 249, 33-43(2002). (Pubitemid 35333430)
62. Katsuma M, Watanabe S, Takemura S. Scitigraphic evaluation of a novel colon-targeted delivery system (CODES™) in healthy volunteers. J. Pharm. Sci. 93, 1287-1299 (2004). (Pubitemid 38529702)